65,437 trials
Osteoarthritis of the Knee
Primary: Pain at Rest (VAS) — 18; 12; 30 Units on a scale — p=0.001
Cystic Fibrosis
Primary: The Safety and Tolerability of a Single-dose of KB001. — 7; 10; 8 Number of participants experiencing AEs
Breast Cancer
Primary: Percentage of Participants With Reoccurrence — 90.7; 87.5 participants
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Arthritis, Rheumatoid
Primary: Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52 — 9.82; 5.19; 3.33 Scores on a scale — p=<0.0001
Healthy
Primary: Lorazepam, Diphenyhydramine, Haloperidol Absorption — 0; .08; 0 ng/ml
Attention Deficit Disorder With Hyperactivity
Primary: Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Score (AISRS) Over Time Using the Diagnostic and Statistical Manual of Mental Disorders…
Aortic Arch Hypoplasia or Atresia
Primary: Intestinal Fatty Acid Binding Protein and C-reactive Protein
Chronic Obstructive Pulmonary Disease
Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.71; 1.79; 1.72; 1.71 L
Hyponatremia
Primary: Incidence of Hyponatremia (Defined as Serum Sodium Less Than 130 mmol/L) — 1; 2; 8 participants — p=<0.05
Periodontal Diseases
Primary: Change in Probing Depth — 2.7; 2.4 mm — p=>.05
Rheumatoid Arthritis
Primary: Mean Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy — 56.48; 56.32; 56.75; 57.55 Days
Multiple Sclerosis
Primary: Median Percent Change From Baseline in Average Walking Speed on Timed 25-Foot Walk Test — 1.2; 7.5; 9.7; 6.9 percent change
Crohn's Disease
Primary: Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26 — 28.4; 38.7 percent of participants…
Influenza
Primary: Seroprotection Rate Infants (6-11 Months)-A/Brisbane/59/07(H1N1) — 41; 34 participants